Tween® Preserves Enzyme Activity and Stability in PLGA Nanoparticles

Abstract

Enzymes, as natural and potentially long-term treatment options, have become one of the most sought-after pharmaceutical molecules to be delivered with nanoparticles (NPs); however, their instability during formulation often leads to underwhelming results. Various molecules, including the Tween® polysorbate series, have demonstrated enzyme activity protection but are often used uncontrolled without optimization. Here, poly(lactic-co-glycolic) acid (PLGA) NPs loaded with β-glucosidase (β-Glu) solutions containing Tween® 20, 60, or 80 were compared. Mixing the enzyme with Tween® pre-formulation had no effect on particle size or physical characteristics, but increased the amount of enzyme loaded. More importantly, NPs made with Tween® 20:enzyme solutions maintained significantly higher enzyme activity. Therefore, Tween® 20:enzyme solutions ranging from 60:1 to 2419:1 mol:mol were further analyzed. Isothermal titration calorimetry analysis demonstrated low affinity and unquantifiable binding between Tween® 20 and β-Glu. Incorporating these solutions in NPs showed no effect on size, zeta potential, or morphology. The amount of enzyme and Tween® 20 in the NPs was constant for all samples, but a trend towards higher activity with higher molar rapports of Tween® 20:β-Glu was observed. Finally, a burst release from NPs in the first hour with Tween®:β-Glu solutions was the same as free enzyme, but the enzyme remained active longer in solution. These results highlight the importance of stabilizers during NP formulation and how optimizing their use to stabilize an enzyme can help researchers design more efficient and effective enzyme loaded NPs.

Quantitative comparison of the protein corona of nanoparticles with different matrices

“…Nanoparticles (NPs) represent one of the most innovative tools in the medical field. They can offer a wide range of potential advantages to drug delivery, such as the ability to a) incorporate a broad range of characteristically diverse active substances ( Duskey et al, 2017 ; Sigg et al, 2016 ; Zu et al, 2021 ); b) stabilize and protect molecules from degradation in different biological environments ( Duskey et al, 2021 ; Duskey et al, 2020a ; Fornaguera and García-Celma, 2017 ); c) be surface-modified for specific targeted delivery (i.e. to tissue, cell types, or intra-cellular receptors) ( Amini et al, 2021 ; Hoyos-Ceballos et al, 2020 ; Pederzoli et al, 2019 ); d) selectively modulate drug release (i.e.…”

Tunneling Nanotubes: A New Target for Nanomedicine?

“…NMeds are defined as nanometricsized delivery systems with a vast range of types that, depending on their specific characteristics, can be optimized to encapsulate, protect, and specifically deliver virtually any kind of therapeutic agent. In particular, the literature results of the last 20 years demonstrate NMeds intelligently designed to (1) improve the solubility of poorly soluble drugs [78,79], (2) stabilize and protect sensitive molecules such as proteins [80][81][82][83], peptides [84][85][86], and genetic material [87,88] from degradation, (3) promote their accumulation into target cells or tissues [89,90], and thereby (4) reduce drug toxicity outside the targeted tissue [91,92], and (5) prolong and/or control the release of the drug over time (Figure 1) [93][94][95][96]. All these properties together make NMeds perfect candidates for the treatment of a plethora of pathologies, especially those considered difficult to treat or that affect difficult-to-reach organs, including neurodegenerative disorders, such as Alzheimer's [97], Parkinson's [98], or Huntington's [99], different types of cancer [100], e.g., breast cancer [101], leukemia [102],…”

Applications of the ROS-Responsive Thioketal Linker for the Production of Smart Nanomedicines

“…Nanoparticles (NPs) and nano-based drug delivery systems (DDS) (such as liposomes, polymeric nanoparticles, dendrimers, etc.) have the remarkable ability to minimize the degradation of therapeutic molecules, prevent harmful side-effects, as well as to increase the fraction of a drug that accumulates at the diseased site [1][2][3][4][5][6][7]; however, success of DDS as approved therapeutic treatments is still limited by certain shortcomings including:…”